Paolo de Fabritiis

University of Rome Tor Vergata

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (5)

Nicola Giuliani

Associate Professor

Università degli Studi di Pavia

ITALY

View details

Renato Zambello

ITALY

View details

ROBERTO MINA

Assistant professor

ITALY

View details

Iole Cordone

IRCCS Regina Elena National Cancer Institute

ITALY

View details

Francesco Buccisano

Associate Professor

UNIVERSITY TOR VERGATA

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Paolo de Fabritiis

Research Interests

Explore related searches

Contact this professor

Articles (10)

Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol

Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study

SARS-CoV-2 infection anxieties and general population restrictions delay diagnosis and treatment of acute haematological malignancies.

Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study

Favorable kidney recovery by extracorporeal light chain removal and anti-myeloma treatments in patients with newly diagnosed multiple myeloma and acute renal failure

Impact of SARS CoV-2 in hemoglobinopathies with immune disfunction and epidemiology. A protective mechanism from beta chain hemoglobin defects?

Collaborators (5)

Nicola Giuliani

Renato Zambello

ROBERTO MINA

Iole Cordone

Francesco Buccisano

Make your next move.